)
Steffen Thirstrup, PhD
Chief Medical Officer
European Medicines Agency (EMA)
Steffen Thirstrup is a medical doctor and board-certified specialist in clinical pharmacology and therapeutics. He holds a PhD in pharmacology and has a long background in clinical internal medicine with special emphasis on adult respiratory medicine.
From 2004-09 Steffen Thirstrup held several positions at the Danish Medicines Agency as Danish member of CHMP at the EMA for five years and CAT-member, later appointed head of Danish Institute for Rational Pharmacotherapy. In 2011 Prof. Thirstrup rejoined the licensing division at the Danish Medicines Agency as Head of Division for Medicines Assessment and Clinical Trials. During this period Prof Thirstrup co-chaired the European Commission’s working group on market access for biosimilars medicinal products and acted as key scientific contact for the managing entity of the IMI beneficiaries for the PROTECT collaboration (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).
In March 2013, Prof Thirstrup joined the pharmaceutical consultancy company NDA Group AB as a full-time medical advisor on NDA’s regulatory advisory board. In April 2014 Prof Thirstrup was appointed as director for the Regulatory Advisory Board at NDA Regulatory Services Ltd.
Since June 2022 Prof Thirstrup has been the Chief Medical Officer at the European Medicines Agency, Amsterdam, The Netherlands
Sessions
-
22-Jun-202623BCWhy Including Children in Clinical Trials Is Good Science: Rethinking Disease Study Design
-
22-Jun-202623BCNovel Endpoints - Use in Rare Disease and Unconsidered Manifestations
-
23-Jun-202631CTailoring Clinical Trials to Rare Disease Patients’ Experiences
-
23-Jun-202623BCGlobal Cooperation in Ultra Rare Diseases - Evidentiary Requirements
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}